Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1

Conditions

Neoplasms 1 Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 5 Cisplatin 5 Gemcitabine 4 trametinib 2 repotrectinib 2 pembrolizumab 2 enzalutamide 2 atezolizumab 2 Surveys and Questionnaires 2 SS1(dsFv)PE38 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiosurgery 2 Paclitaxel 2 Nivolumab 2 Interviews as Topic 2 Docetaxel 2 Cetuximab 2 Carboplatin 2 vinflunine 1 veliparib 1 vadimezan 1 toripalimab 1 talazoparib 1 sintilimab 1 reolysin 1 pixantrone 1 pertuzumab 1 peginterferon alfa-2a 1 palbociclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × imgatuzumab × Tumor-Agnostic × Clear all

NCT04985825 2022-09-13

I-PACE

Centessa Pharmaceuticals plc

Phase 2 Withdrawn

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡